Mereo BioPharma Group (NASDAQ:MREO) Earns Neutral Rating from JPMorgan Chase & Co.

Mereo BioPharma Group (NASDAQ:MREO)‘s stock had its “neutral” rating reiterated by investment analysts at JPMorgan Chase & Co. in a research report issued on Monday, MarketBeat reports.

Several other brokerages also recently weighed in on MREO. Lifesci Capital upgraded Mereo BioPharma Group to a “hold” rating in a report on Thursday, March 19th. Robert W. Baird set a $1.00 price objective on Mereo BioPharma Group in a research note on Monday, December 29th. Wall Street Zen lowered shares of Mereo BioPharma Group from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. BTIG Research reaffirmed a “buy” rating and issued a $1.00 target price on shares of Mereo BioPharma Group in a report on Friday, January 16th. Finally, Jefferies Financial Group downgraded shares of Mereo BioPharma Group from a “buy” rating to a “hold” rating in a research note on Tuesday, December 30th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $3.25.

Mereo BioPharma Group Price Performance

Shares of NASDAQ MREO opened at $0.34 on Monday. The company has a market capitalization of $53.47 million, a P/E ratio of -5.60 and a beta of 0.34. The company has a 50 day simple moving average of $0.43 and a 200-day simple moving average of $1.29. Mereo BioPharma Group has a 1 year low of $0.20 and a 1 year high of $3.05.

Mereo BioPharma Group (NASDAQ:MREO) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). As a group, research analysts expect that Mereo BioPharma Group will post -0.03 EPS for the current year.

Hedge Funds Weigh In On Mereo BioPharma Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Marex Group plc purchased a new position in Mereo BioPharma Group in the 2nd quarter valued at $27,000. State of New Jersey Common Pension Fund D purchased a new position in Mereo BioPharma Group during the 3rd quarter worth $32,000. Virtu Financial LLC acquired a new stake in shares of Mereo BioPharma Group in the 3rd quarter worth $33,000. Graham Capital Management L.P. acquired a new stake in shares of Mereo BioPharma Group in the 4th quarter worth $48,000. Finally, Virtus Investment Advisers LLC boosted its holdings in shares of Mereo BioPharma Group by 199.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 122,595 shares of the company’s stock valued at $51,000 after acquiring an additional 81,665 shares in the last quarter. Hedge funds and other institutional investors own 62.83% of the company’s stock.

Trending Headlines about Mereo BioPharma Group

Here are the key news stories impacting Mereo BioPharma Group this week:

• Positive Sentiment: Reported decline in short interest as of Mar 13 — short interest fell to 11,262,015 shares (down ~18.2% from Feb 26), representing ~7.5% shorted and a days‑to‑cover of ~7.9 on the stated average volume; shorter gross short exposure can remove some downward pressure on the stock.
• Neutral Sentiment: Conflicting short‑interest data for March 24 (multiple feeds showing 0 shares and NaN changes) suggests reporting anomalies; short‑interest metrics may be unreliable until confirmed.
• Neutral Sentiment: JPMorgan reaffirmed a “neutral” rating on MREO, which is neither bullish nor bearish and likely has limited immediate impact. Benzinga
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff participants in a securities class action (class period: 6/5/2023–12/26/2025) and are reminding investors of the April 6, 2026 deadline — this creates legal overhang, potential future liability, and selling pressure as investors reassess risk. See representative notices: Rosen Law Firm. Rosen Law Firm Pomerantz. Pomerantz Bronstein/Gewirtz. Bronstein

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.